Omicron BA.2 sub-lineage has been increasing in many countries in recent months. It’s urgent to investigate immune escape properties and virulence of BA.2. Sino Biological has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants which can be used to evaluate the efficacy of the antibodies and vaccination.